Hunan Hansen Pharmaceutical Co., Ltd. (SHE:002412)
China · Delayed Price · Currency is CNY 7.60
-0.34 (-4.28%)
Nov 13, 2026, 3:04 PM CST
SHE:002412 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,007 | 1,038 | 1,004 | 953.95 | 912.38 | 890.33 |
Other Revenue | 0.53 | 0.53 | 0.81 | 1.58 | 3.68 | 1.5 |
| 1,007 | 1,039 | 1,004 | 955.53 | 916.06 | 891.84 | |
Revenue Growth | -4.20% | 3.41% | 5.12% | 4.31% | 2.72% | 20.32% |
Cost of Revenue | 226.18 | 241.38 | 250.27 | 262.78 | 267.37 | 256.96 |
Gross Profit | 780.94 | 797.38 | 754.2 | 692.75 | 648.69 | 634.88 |
Selling, General & Admin | 501.33 | 501.29 | 461.5 | 456.53 | 449.58 | 451.63 |
Research & Development | 37.1 | 39.04 | 39.32 | 44.48 | 47.9 | 39.45 |
Other Operating Expenses | 19.18 | 18.9 | 17.15 | 18.56 | 17.95 | 17.94 |
Operating Expenses | 559.41 | 559.22 | 517.87 | 519.55 | 515.46 | 508.75 |
Operating Income | 221.53 | 238.16 | 236.33 | 173.2 | 133.23 | 126.13 |
Interest Expense | -0.83 | -1.66 | -2.56 | -3.68 | -3.91 | -6.52 |
Interest & Investment Income | 31.66 | 7.58 | 11.27 | 63.12 | 92.49 | 68.59 |
Other Non Operating Income (Expenses) | -6.95 | -7.32 | -0.31 | -12.16 | -0.26 | -0.26 |
EBT Excluding Unusual Items | 245.4 | 236.75 | 244.73 | 220.48 | 221.56 | 187.93 |
Impairment of Goodwill | -0.06 | -0.06 | - | - | -38.24 | -39.63 |
Gain (Loss) on Sale of Investments | 57.66 | 1.85 | 2.07 | 1.8 | 1.13 | 0.4 |
Gain (Loss) on Sale of Assets | -0.13 | -0.02 | - | -0.02 | - | - |
Asset Writedown | -2.72 | -2.77 | -0.17 | -0.27 | -9.28 | -1.33 |
Other Unusual Items | 3.35 | 2.86 | 6.12 | 4.03 | 6.68 | 2.53 |
Pretax Income | 303.51 | 238.61 | 252.76 | 226.02 | 181.85 | 149.9 |
Income Tax Expense | 31.58 | 40.49 | 32.51 | 21 | 14.24 | 15.05 |
Earnings From Continuing Operations | 271.92 | 198.12 | 220.24 | 205.01 | 167.62 | 134.85 |
Net Income | 271.92 | 198.12 | 220.24 | 205.01 | 167.62 | 134.85 |
Net Income to Common | 271.92 | 198.12 | 220.24 | 205.01 | 167.62 | 134.85 |
Net Income Growth | 58.08% | -10.04% | 7.43% | 22.31% | 24.30% | 27.04% |
Shares Outstanding (Basic) | 503 | 503 | 503 | 503 | 503 | 503 |
Shares Outstanding (Diluted) | 503 | 503 | 503 | 503 | 503 | 503 |
Shares Change | 0.01% | 0.01% | -0.01% | 0.01% | 0.01% | -0.03% |
EPS (Basic) | 0.54 | 0.39 | 0.44 | 0.41 | 0.33 | 0.27 |
EPS (Diluted) | 0.54 | 0.39 | 0.44 | 0.41 | 0.33 | 0.27 |
EPS Growth | 58.06% | -10.05% | 7.44% | 22.31% | 24.29% | 27.07% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 198.05 | 234.28 | 119.15 | 141.47 | 132.3 | -16.8 |
Free Cash Flow Per Share | 0.39 | 0.47 | 0.24 | 0.28 | 0.26 | -0.03 |
Dividend Per Share | 0.300 | 0.300 | - | - | 0.300 | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 77.54% | 76.76% | 75.08% | 72.50% | 70.81% | 71.19% |
Operating Margin | 22.00% | 22.93% | 23.53% | 18.13% | 14.54% | 14.14% |
Profit Margin | 27.00% | 19.07% | 21.93% | 21.46% | 18.30% | 15.12% |
Free Cash Flow Margin | 19.66% | 22.55% | 11.86% | 14.80% | 14.44% | -1.88% |
EBITDA | 261.36 | 278.39 | 277.09 | 224.17 | 184.82 | 177.31 |
EBITDA Margin | 25.95% | 26.80% | 27.59% | 23.46% | 20.18% | 19.88% |
D&A For EBITDA | 39.83 | 40.23 | 40.76 | 50.97 | 51.59 | 51.19 |
EBIT | 221.53 | 238.16 | 236.33 | 173.2 | 133.23 | 126.13 |
EBIT Margin | 22.00% | 22.93% | 23.53% | 18.13% | 14.54% | 14.14% |
Effective Tax Rate | 10.41% | 16.97% | 12.86% | 9.29% | 7.83% | 10.04% |
Revenue as Reported | 1,007 | 1,039 | 1,004 | 955.53 | 916.06 | 891.84 |
Advertising Expenses | - | - | - | - | 111.88 | 92.25 |